ITL and Oncascan Developing Instrument for New Cancer Test

Product News   Jun 18, 2015

 
ITL and Oncascan Developing Instrument for New Cancer Test
 
 
FURTHER INFORMATION
 

Related Product News

BIA Separations and Biomay Collaborate on Production and Purification of Large DNA Plasmids

Product News

Collaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application.

READ MORE

Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

Product News

Two additional licenses granted; upfront payment of US$18 million; total potential transaction value of up to US$484.7 million.

READ MORE

Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients

Product News

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the MammaPrint® Breast Cancer Risk of Recurrence test and BluePrint® Molecular Subtyping test for use in its 18 French Comprehensive Cancer Centers (FCCC).

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE